Aclaris Therapeutics ACRS EBIT

EBIT at other companies

IncyteINCY

$697.9M+31.6%

Corvus PharmaceuticalsCRVS

-$14.88M-49.9%

Upstream Bio, Inc.UPB

-$42.37M+4.5%

Avalo TherapeuticsAVTX

-$31.52M-63.2%

Shattuck Labs, Inc.STTK

-$16.16M-24.0%

Cullinan Therapeutics, Inc.CGEM

-$57.25M+24.5%

FAQ

What is Aclaris Therapeutics's EBIT?

Aclaris Therapeutics (ACRS) reported EBIT of -$24.24M in Q2 2026.

How has Aclaris Therapeutics's EBIT changed year-over-year?

Aclaris Therapeutics's EBIT decreased by 31.7% year-over-year, from -$18.41M to -$24.24M.

What is the long-term trend for Aclaris Therapeutics's EBIT?

Over 4 years (2021 to 2025), Aclaris Therapeutics's EBIT has grown at a -3.9% compound annual growth rate (CAGR), from -$89.72M to -$76.38M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.